Matt Harris's most recent trade in Flywire Corp was a trade of 16,990 Voting Common Stock done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Flywire Corp | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 16,990 | 27,456 | - | 0 | Voting Common Stock | |
| GE Vernova | Matthew Harris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 1,329 | 0 | - | - | Restricted Stock Units | |
| GE Vernova | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 1,329 | 1,329 | - | 0 | Common stock, par value $0.01 per share | |
| GE Vernova | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 495 | 495 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Mar 2025 | 67,787 | 14,069 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 18,550 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 74,000 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 7,775 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 84,564 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 78,898 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 0 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 30 Jan 2025 | 3,173 | 70,827 (0%) | 0% | 7 | 22,211 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,708 | 81,856 (0%) | 0% | 6.6 | 17,981 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,109 | 76,789 (0%) | 0% | 6.6 | 14,004 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 30 Jan 2025 | 1,905 | 72,732 (0%) | 0% | 5.2 | 9,868 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 183,600 | 183,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 63,400 | 63,400 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 69,719 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 43,800 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 4,994 | 64,725 (0%) | 0% | 7.0 | 34,858 | Common Stock, par value $0.0001 |
| Flywire Corp | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2024 | 10,466 | 10,466 | - | 0 | Voting Common Stock | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.41 per share. | 31 Jul 2024 | 1,486 | 55,119 (0%) | 0% | 5.4 | 8,039 | Common Stock, par value $0.0001 |
| GE Vernova | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,329 | 1,329 | - | - | Restricted Stock Units | |
| GE Vernova | Matthew Harris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 695 | 695 | - | - | Common stock, par value $0.01 per share | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 55,965 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 15,550 | - | - | Restricted Stock Units | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 6,166 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 49,991 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 01 Feb 2024 | 2,332 | 53,633 (0%) | 0% | 9.3 | 21,734 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 01 Feb 2024 | 1,801 | 48,190 (0%) | 0% | 9.9 | 17,794 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 43,277 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 27,825 | - | - | Restricted Stock Units | |
| Altimmune Inc | Scott Matthew Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 3,257 | 43,825 (0%) | 0% | 2.7 | 8,761 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 2,709 | 40,568 (0%) | 0% | 9.8 | 26,548 | Common Stock, par value $0.0001 |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 691 | 34,002 (0%) | 0% | 2.8 | 1,942 | Common Stock, par value $0.0001 |
| Flywire Corp | Matt Harris | Director | Other type of transaction at price $ 0.00 per share. | 14 Jun 2023 | 3,553,002 | 242,386 | - | 0 | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director | Sale of securities on an exchange or to another person at price $ 30.98 per share. | 14 Jun 2023 | 191,976 | 50,410 | - | 31.0 | 5,946,841 | Voting Common Stock |
| Flywire Corp | Matt Harris | Director | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 14 Jun 2023 | 50,410 | 0 | - | 31.9 | 1,605,896 | Voting Common Stock |
| Flywire Corp | Matt Harris | Director | Other type of transaction at price $ 0.00 per share. | 24 May 2023 | 3,830,284 | 3,965,104 | - | 0 | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director | Sale of securities on an exchange or to another person at price $ 29.81 per share. | 24 May 2023 | 169,716 | 3,795,388 | - | 29.8 | 5,059,302 | Voting Common Stock |
| Flywire Corp | Matt Harris | Director | Sale of securities on an exchange or to another person at price $ 30.60 per share. | 18 May 2023 | 1,000,000 | 7,795,388 | - | 30.6 | 30,600,000 | Voting Common Stock |
| Flywire Corp | Matt Harris | Director | Sale of securities on an exchange or to another person at price $ 29.51 per share. | 11 May 2023 | 2,850,000 | 8,795,388 | - | 29.5 | 84,103,500 | Voting Common Stock |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.22 per share. | 23 Mar 2023 | 10,000 | 33,311 (0%) | 0% | 4.2 | 42,200 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 23,325 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 25,675 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 02 Feb 2023 | 2,364 | 23,311 (0%) | 0% | 15.0 | 35,555 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 20,083 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 12,332 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 31 Jan 2023 | 2,183 | 17,900 (0%) | 0% | 13.8 | 30,082 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,296 | 13,917 (0%) | 0% | 10.2 | 13,230 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 105,000 | 105,000 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 37,100 | 37,100 | - | - | Restricted Stock Units | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 17 Nov 2022 | 1,903,864 | 11,741,524 | - | 0 | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 20.51 per share. | 17 Nov 2022 | 96,136 | 11,645,388 | - | 20.5 | 1,971,922 | Voting Common Stock |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 25.35 per share. | 15 Aug 2022 | 1,653,986 | 13,645,388 | - | 25.3 | 41,928,545 | Voting Common Stock |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jul 2022 | 1,076 | 12,621 (0%) | 0% | 6.9 | 7,381 | Common Stock, par value $0.0001 |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 19.60 per share. | 03 Jun 2022 | 1,240,490 | 15,299,374 | - | 19.6 | 24,313,604 | Voting Common Stock |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.52 per share. | 28 Feb 2022 | 30,000 | 11,545 (0%) | 0% | 7.5 | 225,600 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,000 | 31,400 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.92 per share. | 28 Feb 2022 | 30,000 | 41,545 (0%) | 0% | 1.9 | 57,639 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 91,600 | 91,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 31,100 | 31,100 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 18,498 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 13,728 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 31 Jan 2022 | 2,183 | 11,545 (0%) | 0% | 8.0 | 17,420 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jan 2022 | 1,800 | 7,562 (0%) | 0% | 6.9 | 12,348 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 31 Jul 2021 | 725 | 5,762 (0%) | 0% | 7.7 | 5,589 | Common Stock, par value $0.0001 |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 21 Jun 2021 | 190,500 | 0 | - | - | Warrants (Right to Buy) | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 21 Jun 2021 | 190,500 | 16,539,864 | - | 1.5 | 281,940 | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 21 Jun 2021 | 75,000 | 0 | - | - | Warrants (Right to Buy) | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 21 Jun 2021 | 75,000 | 16,349,364 | - | 0.2 | 12,750 | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 28 May 2021 | 16,274,364 | 0 | - | - | Class A Common Stock | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 28 May 2021 | 16,274,364 | 16,274,364 | - | - | Voting Common Stock | |
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 7,700,250 | 16,274,364 | - | - | Class A Common Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 7,700,250 | 0 | - | - | Series C Preferred Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 1,540,935 | 8,407,677 | - | - | Class A Common Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 1,540,935 | 0 | - | - | Series B Preferred Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 554,376 | 6,866,742 | - | - | Class A Common Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 554,376 | 0 | - | - | Series A Preferred Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 166,437 | 8,574,114 | - | - | Class A Common Stock | ||
| Flywire Corp | Matt Harris | Director, Ten Percent Owner | 28 May 2021 | 166,437 | 0 | - | - | Series B-1 Preferred Stock | ||
| Argo Group International H... | Matthew J. Harris | Head of International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.79 per share. | 27 Mar 2021 | 376 | 7,104 (0%) | 0% | 50.8 | 19,097 | Common Stock |
| Argo Group International H... | Matthew J. Harris | Head of International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.60 per share. | 16 Mar 2021 | 265 | 7,480 (0%) | 0% | 54.6 | 14,469 | Common Stock |
| Argo Group International H... | Matthew J. Harris | Head of International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 1,362 | 8,006 (0%) | 0% | 0 | Common Stock | |
| Argo Group International H... | Matthew J. Harris | Head of International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 54.79 per share. | 15 Mar 2021 | 261 | 7,745 (0%) | 0% | 54.8 | 14,300 | Common Stock |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 90,000 | 90,000 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units | |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 968 | 5,037 (0%) | 0% | 12.1 | 11,752 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Director | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 12 Nov 2020 | 4,015 | 4,069 (0%) | 0% | 10.0 | 40,230 | Common Stock, par value $0.0001 |
| Altimmune Inc | Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 8,084 | 8,084 (0%) | 0% | 1.5 | 11,803 | Common Stock, par value $0.0001 |